Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly.

We previously described that a short version of the acute octreotide test (sAOT) can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. We have prospectively reassessed the sAOT in patients from the ACROFAST study using current ultra-sensitive GH assays. We also studied the correlation of sAOT with tumor expression of E-cadherin and somatostatin receptor 2 (SSTR2) . A total of 47 patients treated with SRLs for 6 months were evaluated with the sAOT at diagnosis and correlated with SRLs' response. Those patients whose IGF1 decreased to <3SDS from normal value were considered In all, 30 patients were responders and 17 were non-responders. GH The sAOT is a good predictor tool for assessing response to SRLs and correlates with tumor E-cadherin and SSTR2 expression. Thus, it can be useful in clinical practice for therapeutic decision-making in patients with acromegaly.

Informations de copyright

Copyright © 2023 Marques-Pamies, Gil, Valassi, Hernández, Biagetti, Giménez-Palop, Martínez, Carrato, Pons, Villar-Taibo, Araujo-Castro, Blanco, Simón, Simó-Servat, Xifra, Vázquez, Pavón, García-Centeno, Zavala, Hanzu, Mora, Aulinas, Vilarrasa, Librizzi, Calatayud, de Miguel, Alvarez-Escola, Picó, Sampedro, Salinas, Fajardo-Montañana, Cámara, Bernabéu, Jordà, Webb, Marazuela and Puig-Domingo.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.